Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Cardiology · Takotsubo Cardiomyopathy

The Road to Healing: Treatment and Long-Term Recovery

At a Glance

Recovery from Takotsubo cardiomyopathy is typically excellent, with the heart's pumping function usually returning to normal within 4 to 8 weeks. Treatment focuses on supportive care, managing temporary complications, and using medications like beta-blockers or ACE inhibitors to aid healing.

The recovery journey from Takotsubo is often a source of great relief: for most patients, the heart muscle is not permanently damaged and will return to its normal strength [1]. However, the weeks following your hospital stay are a critical “healing window” where your medical team focuses on supportive care and confirming that your heart has fully bounced back [2][3].

Acute Care: Navigating the Obstacles

In the first few days, treatment is highly individualized. There is no single “Takotsubo pill”; instead, doctors manage the symptoms and complications your heart is experiencing [4].

Tailoring Treatment for LVOT Obstruction

If your heart’s shape caused a Left Ventricular Outflow Tract (LVOT) obstruction (a temporary blockage of blood leaving the heart), your medical team will carefully select your medications [5].

  • Instead of using standard heart-stimulating drugs (which can sometimes make the temporary obstruction worse), doctors often use intravenous (IV) fluids to “fill” the heart [6][7].
  • They may also use beta-blockers to slow the heart rate, which gently helps clear the obstruction and stabilize blood pressure [8][9]. Knowing that doctors are carefully monitoring your specific heart shape ensures you are getting the safest care.

The Road to Recovery: 4 to 8 Weeks

The hallmark of Takotsubo is its transient nature. Unlike a heart attack, where muscle death is permanent, the “stunned” cells in Takotsubo usually recover their full pumping power [10][2].

  • Ejection Fraction (LVEF): This is a measurement of how much blood your heart pumps out with each beat. Most patients see their LVEF return to a normal range (55% or higher) within 2 months [2][3].
  • The Follow-Up Echo: You must have a follow-up echocardiogram or Cardiac MRI scheduled for 4 to 8 weeks after your event [11]. This is the only way for your doctor to confirm the “ballooning” has resolved and your heart has regained its shape [1].
  • Lingering Effects: Even after your pumping strength returns to normal, some cellular-level changes in how your heart handles calcium and energy may persist for 3 months or longer [12]. This explains why many patients feel lingering fatigue even after being told their heart looks “fine” on an ultrasound. Your fatigue is real and a normal part of the healing process.

Long-Term Medications and Prevention

Because the evidence for Takotsubo is still evolving, there is no universal consensus on long-term medication [4][13]. Your doctor will likely tailor your prescriptions based on your specific health history.

  • ACE Inhibitors / ARBs: These medications support heart remodeling and lower blood pressure [14]. Some data suggest they may help prevent the condition from returning, though more study is needed [14][15].
  • Beta-Blockers: These help lower the heart’s sensitivity to adrenaline (stress hormones) [16]. While they may not completely prevent a future “broken heart” episode, they are frequently used for overall heart protection [16][15].

The most important “treatment” for the long term is identifying and managing your triggers, which you can read more about in Life After a Broken Heart.

Common questions in this guide

How long does it take to recover from Takotsubo cardiomyopathy?
Most patients see their heart's pumping power, or ejection fraction, return to a normal range within 4 to 8 weeks. However, you may experience lingering fatigue for three months or longer as your heart cells fully heal on a microscopic level.
What is LVOT obstruction in Takotsubo?
Left Ventricular Outflow Tract (LVOT) obstruction is a temporary blockage of blood leaving the heart, caused by the heart's changed shape. Doctors manage this by carefully using IV fluids and beta-blockers instead of standard heart-stimulating drugs.
What medications are prescribed after Takotsubo cardiomyopathy?
Doctors often prescribe ACE inhibitors, ARBs, and beta-blockers during recovery. These medications help lower blood pressure, support the heart's healing process, and reduce the heart's sensitivity to stress hormones.
Will I need follow-up heart tests after going home?
Yes, you will need a follow-up echocardiogram or cardiac MRI about 4 to 8 weeks after your initial event. This follow-up imaging is essential to confirm that the temporary ballooning has resolved and your heart has regained its normal shape.
Why do I still feel tired even though my heart ultrasound is normal?
Even after your heart's pumping strength returns to normal on an ultrasound, cellular-level changes in how your heart handles energy can persist. This lingering fatigue is a real and normal part of the healing process that can last for several months.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my heart's ejection fraction at discharge, and what is our target for my 4-to-8-week follow-up?
  2. 2.Since I had [or did not have] LVOT obstruction, how does that affect the specific heart medications you are prescribing for me?
  3. 3.How long should I stay on ACE inhibitors or beta-blockers if my heart function returns to 100%?
  4. 4.Are there any specific medications or supplements (like certain cold medicines or stimulants) I should avoid to prevent another surge of stress hormones?
  5. 5.What is my specific plan for managing the emotional or physical trigger that caused this episode?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    [Takotsubo cardiomyopathy].

    Dujardin JJ, Belle L, Yayehd K, Georges JL

    La Revue du praticien 2019; (69(8)):877-880.

    PMID: 32237653
  2. 2

    Temporarily increased stroke rate after Takotsubo syndrome: need for an anticoagulation?

    Abanador-Kamper N, Kamper L, Wolfertz J, et al.

    BMC cardiovascular disorders 2018; (18(1)):117 doi:10.1186/s12872-018-0842-0.

    PMID: 29907089
  3. 3

    Novel Understanding of Takotsubo Syndrome.

    Watanabe M, Izumo M, Akashi YJ

    International heart journal 2018; (59(2)):250-255 doi:10.1536/ihj.17-586.

    PMID: 29503405
  4. 4

    Is modulation (desensitization) of the beta-adrenergic receptors a cause or an epiphenomenon of takotsubo syndrome?

    Madias JE

    Journal of cardiology 2021; (77(5)):552 doi:10.1016/j.jjcc.2021.01.008.

    PMID: 33618974
  5. 5

    Mechanical Circulatory Support With Impella Percutaneous Ventricular Assist Device as a Bridge to Recovery in Takotsubo Syndrome Complicated by Cardiogenic Shock and Left Ventricular Outflow Tract Obstruction.

    Beneduce A, Fausta Bertoldi L, Melillo F, et al.

    JACC. Cardiovascular interventions 2019; (12(4)):e31-e32 doi:10.1016/j.jcin.2018.10.046.

    PMID: 30711550
  6. 6

    Refractory Acute Myocardial Infarction Cardiogenic Shock Due to Left Ventricular Outflow Tract Obstruction.

    Akinmolayemi O, Beerkens FJ, Hu V, et al.

    JACC. Case reports 2025; (30(23)):104452 doi:10.1016/j.jaccas.2025.104452.

    PMID: 40816853
  7. 7

    Tailored Therapies for Cardiogenic Shock in Hypertrophic Cardiomyopathy: Navigating Emerging Strategies.

    Zakynthinos GE, Gialamas I, Tsolaki V, et al.

    Journal of cardiovascular development and disease 2024; (11(12)) doi:10.3390/jcdd11120401.

    PMID: 39728291
  8. 8

    Norepinephrine and Dobutamine-Induced Dynamic Left Ventricular Outflow Tract Obstruction Caused by Systolic Anterior Motion.

    Hung TD, Ha PVT, Chien DV

    Journal of medical cases 2024; (15(4-5)):67-71 doi:10.14740/jmc4204.

    PMID: 38715913
  9. 9

    A handicap in Takotsubo cardiomyopathy: dynamic outflow obstruction.

    Keskin M, Tanık VO, Gümüşdağ A, Yıldırımtürk Ö

    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2016; (44(2)):161-5 doi:10.5543/tkda.2015.32762.

    PMID: 27111317
  10. 10

    Takotsubo syndrome.

    Gupta S, Gupta MM

    Indian heart journal 2018; (70(1)):165-174 doi:10.1016/j.ihj.2017.09.005.

    PMID: 29455773
  11. 11

    Takotsubo Cardiomyopathy in a Case of Intracerebral Hemorrhage: A Case Report.

    Nagpal RR, Dhabhar JB, Ghanekar J

    Cureus 2019; (11(9)):e5711 doi:10.7759/cureus.5711.

    PMID: 31720179
  12. 12

    Manganese-Enhanced Magnetic Resonance Imaging in Takotsubo Syndrome.

    Singh T, Joshi S, Kershaw LE, et al.

    Circulation 2022; (146(24)):1823-1835 doi:10.1161/CIRCULATIONAHA.122.060375.

    PMID: 36317524
  13. 13

    Takotsubo Cardiomyopathy: Current Treatment.

    Madias JE

    Journal of clinical medicine 2021; (10(15)) doi:10.3390/jcm10153440.

    PMID: 34362223
  14. 14

    Takotsubo cardiomyopathy: Review of broken heart syndrome.

    Boyd B, Solh T

    JAAPA : official journal of the American Academy of Physician Assistants 2020; (33(3)):24-29 doi:10.1097/01.JAA.0000654368.35241.fc.

    PMID: 32039951
  15. 15

    Beta-blockers and renin-angiotensin system inhibitors for Takotsubo syndrome recurrence: a network meta-analysis.

    Santoro F, Sharkey S, Citro R, et al.

    Heart (British Cardiac Society) 2024; (110(7)):476-481 doi:10.1136/heartjnl-2023-322980.

    PMID: 37666647
  16. 16

    Beta-Blockers and Long-Term Mortality in Takotsubo Syndrome: Results of the Multicenter GEIST Registry.

    Raposeiras-Roubin S, Santoro F, Arcari L, et al.

    JACC. Heart failure 2025; (13(5)):815-825 doi:10.1016/j.jchf.2024.11.015.

    PMID: 39918532

This page is for informational purposes only and does not replace professional medical advice. Always consult your cardiologist regarding your specific Takotsubo recovery timeline and medication plan.

Get notified when new evidence is published on Tako-Tsubo cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.